MedTrace Logo

Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting

NCT03912883 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 3350

Last updated 2025-11-18

No results posted yet for this study

Summary

The Trans-Atlantic Prostate Group (TAPG) was established to examine the hypothesis that through a detailed retrospective analysis of outcome in a group of men with clinically localised prostate cancer at diagnosis, variables such as biological, pathological and clinical markers, could be identified that might accurately predict the prognosis of clinically localised prostate cancer.

Conditions

Sponsors & Collaborators

  • Queen Mary University of London

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-12
Primary Completion
2030-01-01
Completion
2030-01-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03912883 on ClinicalTrials.gov